Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)

被引：24
|
作者：
Souto, Selma B. [1 ,2 ]
Souto, Eliana B. [3 ,4 ]
Braga, Daniel C. [1 ,2 ]
Medina, Jose L. [2 ]
机构：
[1] Hosp Sao Joao, Dept Endocrinol, P-4200319 Oporto, Portugal
[2] Univ Porto, Fac Med, P-4200319 Oporto, Portugal
[3] Univ Tras Os Montes & Alto Douro CGB UTAD IBB, Ctr Genom & Biotechnol, Inst Biotechnol & Bioengn, P-5001801 Vila Real, Portugal
[4] Fernando Pessoa Univ, Fac Hlth Sci, P-4200150 Oporto, Portugal
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 67卷 / 07期
关键词：
Impaired glucose tolerance; Pre-diabetes; Prevention; Type; 2; diabetes; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; WEIGHT-LOSS; CARDIOVASCULAR MORBIDITY; CONVENTIONAL THERAPY; INSULIN-RESISTANCE; BLOOD-GLUCOSE; RISK-FACTORS; OBESE; BEZAFIBRATE;
D O I：
10.1007/s00228-011-1038-z
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The urgent need to treat type 2 diabetes mellitus (T2DM), which is currently reaching epidemic proportions, has been a major focus of healthcare systems and policy makers worldwide. Pharmacological treatment and lifestyle interventions together with the control of cardiovascular risk factors are the main strategies to prevent or delay the onset of T2DM. The present review discusses the state of the art knowledge of effective therapeutic approaches (metformin, thiazolidinediones, nateglinides, alpha-glucosidase inhibitors, incretin-based and angiotensin-based therapies, weight reducers, statins, fibric acid derivatives), including surgery, and identifies the major lifestyle changes for specific target groups.
引用
收藏
页码：653 / 661
页数：9
相关论文
共 50 条
  • [1] Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)
    Selma B. Souto
    Eliana B. Souto
    Daniel C. Braga
    José L. Medina
    European Journal of Clinical Pharmacology, 2011, 67 : 653 - 661
  • [2] Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
    Luo, Jian-Quan
    Shu, Yan
    Zhang, Wei
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [3] Vascular responsiveness in type 2 diabetes mellitus (T2DM)
    Blum, A.
    Socea, D.
    Sirchan, R.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (12) : 791 - 796
  • [4] The platelets characteristics in type 2 diabetes mellitus (T2DM)
    Buryachkovskaya, L.
    Uchitel, I. A.
    Sumarokov, A. B.
    Docenko, U., V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 931 - 931
  • [5] Microvascular complications in type 2 diabetes mellitus (T2DM).
    Cheung, AT
    Ramanujam, S
    Duong, PL
    Schauer, D
    Chan, LS
    Dwyre, DM
    Larkin, EC
    FASEB JOURNAL, 2002, 16 (04): : A208 - A208
  • [6] THE PREVALENCE OF MICROALBUMINURIA IN CHILDREN WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Yafi, Michael
    ARCHIVES OF DISEASE IN CHILDHOOD, 2019, 104 : A250 - A250
  • [7] Gut microbiota influence in type 2 diabetes mellitus (T2DM)
    A. L. Cunningham
    J. W. Stephens
    D. A. Harris
    Gut Pathogens, 13
  • [8] Regional effects of type 2 diabetes mellitus (T2DM) on neurodegeneration
    Moran, C.
    Phan, T. G.
    Beare, R. J.
    Chen, J.
    Blizzard, L.
    Venn, A.
    Greenaway, T.
    Munch, G.
    Forbes, J.
    Pearson, S.
    Srikanth, V
    INTERNATIONAL JOURNAL OF STROKE, 2012, 7 : 20 - 20
  • [9] Pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Tan, Z.
    Pang, W. H.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    DIABETIC MEDICINE, 2008, 25
  • [10] Gut microbiota influence in type 2 diabetes mellitus (T2DM)
    Cunningham, A. L.
    Stephens, J. W.
    Harris, D. A.
    GUT PATHOGENS, 2021, 13 (01)
12345